The META-AF Trial

Why It Matters

Demonstrating a benefit would repurpose a low‑cost diabetes drug to enhance AF ablation success, potentially lowering procedural costs and improving patient outcomes.

Key Takeaways

• Randomized, double‑blind trial enrolling 500 AF patients undergoing ablation.
• Metformin dose: 500 mg twice daily, started 2 weeks pre‑procedure.
• Primary endpoint: 12‑month AF recurrence measured by Holter monitoring.
• If positive, could lower repeat ablation rates and healthcare costs.

Pulse Analysis

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia, affecting over 6 million Americans and driving substantial hospital admissions. Catheter ablation is the cornerstone of rhythm control for symptomatic patients, yet recurrence rates hover around 30‑40 % within a year, prompting clinicians to seek adjunctive therapies that can stabilize the post‑procedure substrate. Metformin, a first‑line oral agent for type‑2 diabetes, has emerged in pre‑clinical models as a modulator of cardiac electrophysiology and inflammation, suggesting a plausible role in reducing atrial remodeling after ablation.

The META‑AF trial, a multicenter, double‑blind, placebo‑controlled study, enrolls approximately 500 adults with paroxysmal or persistent AF scheduled for radiofrequency or cryoballoon ablation. Participants receive either metformin 500 mg twice daily or matching placebo starting two weeks before the procedure and continuing for 12 months. The primary endpoint is documented AF recurrence at one year, captured via implantable loop recorders and periodic Holter monitoring. Secondary measures include procedural complications, quality‑of‑life scores, and healthcare utilization, providing a comprehensive view of metformin’s clinical impact beyond glycemic control.

If the trial confirms that metformin reduces AF recurrence, the implications could ripple across cardiology and pharmaceutical markets. A low‑cost, widely available drug could become a standard adjunct to ablation, decreasing the need for repeat interventions and associated expenditures that exceed $30,000 per procedure. Moreover, positive findings would reinforce the growing trend of drug repurposing, encouraging further investigation of metabolic agents in electrophysiology and potentially expanding metformin’s therapeutic label. Such outcomes would benefit patients, providers, and payers alike, aligning with value‑based care initiatives.